

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Magali Hickey et al.  
Serial No. : 10/599,010 Art Unit:  
Filed : September 18, 2006 Examiner:  
For : NOVEL PHARMACEUTICAL FORMS, AND METHODS OF MAKING  
AND USING THE SAME

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified

application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/TPI5053USPCT1/PB.

Respectfully submitted.

Dated: November 9, 2006  
Transform Pharmaceuticals, Inc.  
c/o Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933  
Telephone: (781) 674-7816  
Facsimile: (732) 524-2808

/Paul Burgess/  
Paul Burgess, Attorney for Applicants  
Reg. No. 53,852  
Customer No. 27777

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Substitute for form 1449A/PTO		Application Number	10/599,010
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date	09/18/2006
(use as many sheets as necessary)		First Named Inventor	Magali Hickey
Sheet 1 of 1		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	TP15053USPCT1

## FOREIGN PATENT DOCUMENTS

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature	Date Considered	
-----------------------	--------------------	--

**\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/599,010
Filing Date	09/18/2006
First Named Inventor	Magali Hickey
Group Art Unit	
Examiner Name	
Attorney Docket Number	TP15053USPCTT

**U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--